Nick Galakatos, Blackstone global head of life sciences
Nick Galakatos and the Blackstone team now have a record $4.6B to invest in biopharma, with a big focus on pushing companies over the top
Nick Galakatos and his team at Blackstone Life Sciences have seen their biggest opportunities swell up in mostly established players who don’t have all the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
